kmph.o KemPharm, Inc.

entrato oggi 2.47
 
sempre in p.m.c 2.42 pezzi :p
 
Avio, questa è tua :) e da qui al 2 marzo potrebbe volare forte.
Pdfua 2 marzo
Ha fatto un R/S da poco ed il 27 gennaio ha fatto pure adc, quindi dovrebbe essere a buon prezzo in questo range di oggi.
Very low float.
Io non le ho ancora, ma probabilmente in ottica swing/intra ci entro se non tocca rincorrerla.


Per quanto possano valere i target degli analisti... cmq servono a riferimento...

KMPH
Roth Capital Initiates Coverage On KemPharm with Buy Rating, Announces Price Target of $28
BZ Wire
Roth Capital analyst Jonathan Aschoff initiates coverage on KemPharm (NASDAQ:KMPH) with a Buy rating and announces Price Target of $28.



KMPH KemPharm, Inc. Stock Quote notare quante azioni ci sono.
 
Ultima modifica:
Avio, questa è tua :) e da qui al 2 marzo potrebbe volare forte.
Pdfua 2 marzo
Ha fatto un R/S da poco ed il 27 gennaio ha fatto pure adc, quindi dovrebbe essere a buon prezzo in questo range di oggi.
Very low float.
Io non le ho ancora, ma probabilmente in ottica swing/intra ci entro se non tocca rincorrerla.


Per quanto possano valere i target degli analisti... cmq servono a riferimento...

KMPH
Roth Capital Initiates Coverage On KemPharm with Buy Rating, Announces Price Target of $28
BZ Wire
Roth Capital analyst Jonathan Aschoff initiates coverage on KemPharm (NASDAQ:KMPH) with a Buy rating and announces Price Target of $28.



KMPH KemPharm, Inc. Stock Quote notare quante azioni ci sono.

OK!
 
Vivi (Biotech Queen) Returns | $BCRX $KMPH | ZingerNation - YouTube

kmph report.png
 
Avio, questa è tua :) e da qui al 2 marzo potrebbe volare forte.
Pdfua 2 marzo
Ha fatto un R/S da poco ed il 27 gennaio ha fatto pure adc, quindi dovrebbe essere a buon prezzo in questo range di oggi.
Very low float.
Io non le ho ancora, ma probabilmente in ottica swing/intra ci entro se non tocca rincorrerla.


Per quanto possano valere i target degli analisti... cmq servono a riferimento...

KMPH
Roth Capital Initiates Coverage On KemPharm with Buy Rating, Announces Price Target of $28
BZ Wire
Roth Capital analyst Jonathan Aschoff initiates coverage on KemPharm (NASDAQ:KMPH) with a Buy rating and announces Price Target of $28.



KMPH KemPharm, Inc. Stock Quote notare quante azioni ci sono.
ma che ci sei tornato a fare qui?:o io ormai non leggo piu molto questa sezione
cmq me la studio un po
 
ma che ci sei tornato a fare qui?:o io ormai non leggo piu molto questa sezione
cmq me la studio un po

Ehehe, in realtà sono sempre stato, ma nella sezione Trading Online :) .
Questa potrebbe essere un razzo, ma occhio a non rincorrerla (ancher se per ora i livelli son bassi considerando il catalyst vicino (2marzo), solo 11 Milioni di azioni, adc fatto appena 1 settimana fà e r/s non molto prima. Diciamo che unico rischio, da non sottovalutare , è una eventuale risposta negativa da FDA che arrivi in anticipo. Tutto può succede ma ci vorrebbe sfiga, in questo periodo di Covid che vadano avanti col lavoro... mah (e cmq potrebbe anche andare bene, ma noi non lo vogliono sapere il risultato con le azioni in portfolio, quindi solo runup e/ intra/swing per poco tempo)

Allena l'inglese anche te, hahaha
 
a naso non è che mi piaccia molto:
tem 1.01 Entry into a Material Definitive Agreement.



As previously reported, on January 13, 2021, KemPharm, Inc., a Delaware corporation (the “Company”), consummated an underwritten public offering of 6,765,463 shares of common stock of the Company, pre-funded warrants to purchase 926,844 shares of common stock and warrants to purchase 7,692,307 shares of common stock at an exercise price per share of $6.50 (the “Existing Warrants”) pursuant to a Registration Statement on Form S-1 (File No. 333-250945) and a related prospectus, in each case filed with the Securities and Exchange Commission (the “SEC”). The offering price to the public was $6.50 per share of common stock and accompanying warrant, representing a public offering price of $6.4999 per share of common stock and $0.0001 per related warrant. On January 8, 2021, the underwriter of the public offering exercised its over-allotment option, in part, for additional Existing Warrants to purchase 754,035 shares of common stock.



Warrant Exercise Inducement Letters and Issuance of Warrants



On January 26, 2021, the Company entered into warrant exercise inducement offer letters (“Inducement Letters”) with certain holders of Existing Warrants (collectively, the “Exercising Holders”) pursuant to which such holders agreed to exercise for cash their Existing Warrants to purchase 6,620,358 shares of the Company’s common stock in exchange for the Company’s agreement to issue new warrants (the “Inducement Warrants”) on substantially the same terms as the Existing Warrants, except as set forth in the following sentence, to purchase up to 7,944,430 shares of the Company’s common stock, which is equal to 120% of the number of shares of the Company’s common stock issued upon exercise of the Existing Warrants. The purchase price of the Inducement Warrants will be $0.125 per share underlying each Inducement Warrant, and the Inducement Warrants will have an exercise price of $6.36 per share. The Company expects to receive aggregate gross proceeds of approximately $44.0 million from the exercise of the Existing Warrants by the Exercising Holders and the sale of the Inducement Warrants. The Company has engaged Roth Capital Partners, LLC (“Roth”) as its exclusive placement agent in connection with these transactions and will pay Roth a fee equal to 6% of its gross proceeds from the exercise of the Existing Warrants by the Exercising Holders and the sale of the Inducement Warrants.



The Company also agreed to file a registration statement covering the resale of the shares of the Company’s common stock issued or issuable upon the exercise of the Inducement Warrants no later than 10 calendar days following the date of the Inducement Letters.

cmq la rimetto in wl
 
a naso non è che mi piaccia molto:
tem 1.01 Entry into a Material Definitive Agreement.



As previously reported, on January 13, 2021, KemPharm, Inc., a Delaware corporation (the “Company”), consummated an underwritten public offering of 6,765,463 shares of common stock of the Company, pre-funded warrants to purchase 926,844 shares of common stock and warrants to purchase 7,692,307 shares of common stock at an exercise price per share of $6.50 (the “Existing Warrants”) pursuant to a Registration Statement on Form S-1 (File No. 333-250945) and a related prospectus, in each case filed with the Securities and Exchange Commission (the “SEC”). The offering price to the public was $6.50 per share of common stock and accompanying warrant, representing a public offering price of $6.4999 per share of common stock and $0.0001 per related warrant. On January 8, 2021, the underwriter of the public offering exercised its over-allotment option, in part, for additional Existing Warrants to purchase 754,035 shares of common stock.



Warrant Exercise Inducement Letters and Issuance of Warrants



On January 26, 2021, the Company entered into warrant exercise inducement offer letters (“Inducement Letters”) with certain holders of Existing Warrants (collectively, the “Exercising Holders”) pursuant to which such holders agreed to exercise for cash their Existing Warrants to purchase 6,620,358 shares of the Company’s common stock in exchange for the Company’s agreement to issue new warrants (the “Inducement Warrants”) on substantially the same terms as the Existing Warrants, except as set forth in the following sentence, to purchase up to 7,944,430 shares of the Company’s common stock, which is equal to 120% of the number of shares of the Company’s common stock issued upon exercise of the Existing Warrants. The purchase price of the Inducement Warrants will be $0.125 per share underlying each Inducement Warrant, and the Inducement Warrants will have an exercise price of $6.36 per share. The Company expects to receive aggregate gross proceeds of approximately $44.0 million from the exercise of the Existing Warrants by the Exercising Holders and the sale of the Inducement Warrants. The Company has engaged Roth Capital Partners, LLC (“Roth”) as its exclusive placement agent in connection with these transactions and will pay Roth a fee equal to 6% of its gross proceeds from the exercise of the Existing Warrants by the Exercising Holders and the sale of the Inducement Warrants.



The Company also agreed to file a registration statement covering the resale of the shares of the Company’s common stock issued or issuable upon the exercise of the Inducement Warrants no later than 10 calendar days following the date of the Inducement Letters.

cmq la rimetto in wl

Certo, non è che è crollata per nulla in quel momento, ma ormai dovrebbe aver scontato ed un runup ci stà tutto. Vediamo.
 
sicuro che si gode. però continuo a non capire il target dei 7,20... non ci sta niente a 7,20.

No, ma pochi cents sopra cc'è l'ema 20 sul daily e non penso abbia la forza di superarla oggi. Di solito preferisco mettermi sotto di alcuni cents da obiettivi ccome quello.

PS: poi se mi sbaglio e supera meglio per voi che le tenete:) io mi accontenterei bene.
 
No, ma pochi cents sopra cc'è l'ema 20 sul daily e non penso abbia la forza di superarla oggi. Di solito preferisco mettermi sotto di alcuni cents da obiettivi ccome quello.

PS: poi se mi sbaglio e supera meglio per voi che le tenete:) io mi accontenterei bene.


guarda, che se la tua bella analisi iniziale, va a buon fine, te la ritrovi alle quotazioni di fine novembre...
 
guarda, che se la tua bella analisi iniziale, va a buon fine, te la ritrovi alle quotazioni di fine novembre...

Certo, ma a me non interessa andare oltre l'intraday, massimo un piccolo swing di uno o due giorni.
Si compra la mattina si vende prima del close a meno che no nvalga la pena il piccolo swing.
Altri tempi il runup...
 
Indietro